1219168-18-9

Basic information

• Product Name: BML-275
• Synonyms: dorsoMorphin (Hydrochloride);DorsoMorphin, Dihydrochloride Salt, >99%;6-[4-[2-(1-Piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)pyrazolo[1,5-a]pyrimidine hydrochloride (1:2);BML-275,Compound C;6-[4-[2-(1-Piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)pyrazolo[1,5-a]pyrimidine hydrochloride (1:2) Dorsomorphin 2HCl;Dorsomorphin-2HCl BML-275;BML-275 dihydrochloride;Dorsomorphin(BML-275)dihydrochloride
• CAS NO: 1219168-18-9
• Molecular Formula: C24H27Cl2N5O
• Molecular Weight: 472.41008
• Product Categories: PI3K/Akt/mTOR;Inhibitors;Akt;mTOR;PI3K
• Mol File: 1219168-18-9.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: insoluble in EtOH; insoluble in H2O; ≥11.34 mg/mL in 0.9% NS ; ≥39.93 mg/mL in DMSO:H2O=2:1 ; ≥5.91 mg/mL in DMSO
• CAS DataBase Reference: BML-275(CAS DataBase Reference)
• NIST Chemistry Reference: BML-275(1219168-18-9)
• EPA Substance Registry System: BML-275(1219168-18-9)

Safety Data

• Hazardous Substances Data: 1219168-18-9(Hazardous Substances Data)

Usage

Description

BML-275 is a potent, reversible inhibitor of AMP kinase (AMPK) with a Ki value of 109 nM. It selectively inhibits the bone morphogenetic protein (BMP) type I receptors ALK2, ALK3, and ALK6, blocking BMP-mediated SMAD1/5/8 phosphorylation, target gene transcription, and osteogenic differentiation. BML-275 can also dose-dependently inhibit the bone morphogenetic protein type 1 receptors ACTR-I (ALK2), BMPR-IA (ALK3), and BMPR-IB (ALK6). Additionally, BML-275 has been shown to downregulate the Akt/mTOR pathway to induce autophagy in U251 human glioma cells.

Uses

Used in Pharmaceutical Industry:
BML-275 is used as an AMP-activated kinase (AMPK) inhibitor for its ability to selectively inhibit the bone morphogenetic protein type I receptors ALK2, ALK3, and ALK6. This inhibition blocks BMP-mediated SMAD1/5/8 phosphorylation, target gene transcription, and osteogenic differentiation, making it a potential candidate for the development of therapeutic agents targeting various diseases.
Used in Cancer Research:
BML-275 is used as a research tool to study the role of AMPK and BMP signaling pathways in cancer. Its ability to increase cisplatin-induced apoptosis and downregulate the Akt/mTOR pathway to induce autophagy in cancer cells makes it a valuable compound for investigating the mechanisms of cancer progression and the development of novel therapeutic strategies.
Used in Drug Discovery:
BML-275 is used as a starting point for the development of new drugs targeting AMPK and BMP signaling pathways. Its potent and selective inhibition of these pathways makes it a promising candidate for the design and synthesis of new compounds with improved pharmacological properties and therapeutic potential.